The role of PET imaging in immuno-oncology

Immunotherapy has shown promising outcomes in multiple cancer types and is considered a breakthrough technology when it comes to anti-cancer therapies within cancer care strategies. Despite the prolonged clinical response achieved, response rate is low and variable. For this reason, the use of biomarkers or more effectively, in vivo imaging biomarkers, like PET probes, has great potential to improve response evaluation in patients receiving immunotherapy.

This webinar is already ready over. Missed the live webinar or want to rewatch it?

Speakers

Dr Jelena Levi, PhD

Chief Scientific Officer

CellSight Technologies, US
Dr Anna Wu, PhD

Professor and Chair, Department of Molecular Imaging and Therapy and Co-Director, Center for Theranostic Studies, Beckman Research, and Professor in the Department of Radiation Oncology

City of Hope National Medical Center in Duarte, Canada
Topics
- ImmunoPET for imaging immune responses - 18F labeled agents
- ImmunoPET: Engineered antibodies for imaging immune responses